Peptide Receptor Radionuclide Therapy (PRRT)
3 Vues
• 07/09/23
0
0
Intégrer
administrator
Les abonnés
One of the most significant treatment options for neuroendocrine cancer patients became available with the 2018 FDA approval of Lutathera®, the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT).
NET experts Dr. Emily Bergsland, Dr. Pamela Kunz, Dr. Erik Mittra and Dr.
Jonathan Strosberg describe the treatment, how it works, and the benefits for patients.
What do physicians look forward to in the future for PRRT?
Montre plus
Commentaires de Facebook
SORT BY-
Meilleures Commentaires
-
Derniers Commentaires